Skip to main content
德源药业 logo

德源药业 — Investor Relations & Filings

Ticker · 920735 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 569 across all filing types
Latest filing 2022-08-11 Transaction in Own Shar…
Country CN China
Listing Beijing Stock Exchange 920735

About 德源药业

http://www.pharmdy.com

Deyuan Pharmaceutical specializes in the research, development, production, and commercialization of therapeutic drug preparations. The company focuses on chronic disease management, particularly in the fields of endocrinology and cardiovascular health. Its core product line includes treatments for diabetes, hypertension, and hyperlipidemia, featuring medications such as Metformin Hydrochloride sustained-release tablets, Pioglitazone Hydrochloride, and Valsartan. The organization emphasizes technological innovation and maintains rigorous quality control standards across its manufacturing processes. By leveraging advanced formulation technologies, the company develops high-efficacy pharmaceutical solutions aimed at addressing the long-term needs of patients with metabolic and circulatory disorders.

Recent filings

Filing Released Lang Actions
股权激励计划限制性股票解除限售公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement regarding the lifting of restrictions on a certain number of restricted shares under an equity incentive plan. It details the number of shares being unlocked, the shareholders involved, their roles, and the reasons for the unlocking. It also includes tables showing the shareholding changes and confirms compliance with relevant laws and regulations. There is no financial performance data, no audit information, no management discussion of financial results, no earnings highlights, no merger or acquisition details, and no voting results. The document is a formal announcement about changes in share restrictions related to stock incentives, which fits the category of Transaction in Own Shares (POS) because it involves changes in the company's own shares' status (restricted to unrestricted). The document length is sufficient and contains detailed data, so it is not a mere announcement of a report or a certification. Therefore, the best classification is POS.
2022-08-11 Chinese
国浩律师（南京）事务所关于江苏德源药业股份有限公司2021年限制性股票激励计划第一个解除限售期解除限售条件成就及部分限制性股票回购注销事项之法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the company's 2021 restricted stock incentive plan, specifically about the first unlocking of restricted stock and partial repurchase and cancellation of restricted shares. It contains detailed legal review, approvals, authorizations, and compliance with relevant laws and regulations. The document is not a financial report, earnings release, or management discussion but a legal opinion related to stock incentive plan implementation and share repurchase/cancellation. This fits best under the category of Regulatory Filings (RNS) as it is a legal compliance document and does not match other more specific categories like Capital/Financing Update or Transaction in Own Shares, since it is a legal opinion rather than an announcement or report of the transaction itself.
2022-07-27 Chinese
投资者关系管理制度
Governance Information Classification · 95% confidence The document is titled as an "Investor Relations Management System" issued by the company's board, detailing the company's policies, principles, organizational structure, and procedures for managing investor relations. It includes sections on communication with investors, handling of investor inquiries, disclosure practices, and crisis management related to investor relations. There are no financial statements, earnings data, or audit information. The document is a governance-related policy document rather than a financial report or announcement. It is not a report publication announcement or a brief notice but a detailed internal governance document. Therefore, the most appropriate classification is Governance Information (CGR).
2022-07-27 Chinese
关于拟修订公司章程公告
Governance Information Classification · 95% confidence The document is an announcement from Jiangsu Deyuan Pharmaceutical Co., Ltd. regarding proposed amendments to the company's Articles of Association (公司章程). The amendments relate to changes in registered capital and share capital due to a share repurchase and cancellation following a restricted stock incentive plan. The document includes details of the changes, the reason for the amendments, and references a board resolution. It is not a full report like an Annual Report or Interim Report, nor is it a regulatory certification or voting result. It is a formal announcement about changes in company governance documents (Articles of Association) and capital structure. Given the nature of the content focusing on amendments to the Articles of Association, this fits best under Governance Information (CGR). The document length is short and it is not merely announcing the publication of a report, so it is not RPA or RNS. Therefore, the classification is CGR with high confidence.
2022-07-27 Chinese
重大信息内部报告制度
Governance Information Classification · 95% confidence The document is titled as an internal reporting system for major information of Jiangsu Deyuan Pharmaceutical Co., Ltd., approved by the board of directors. It details the procedures, responsibilities, and scope of reporting significant company information internally, including definitions of major information, reporting obligations, and management of such reports. It is a governance-related document focusing on internal rules and processes for information disclosure and compliance with regulatory requirements. There is no financial data, earnings information, or announcement of voting results. It is not a report publication announcement but a detailed governance policy document. Therefore, the document fits best under Governance Information (CGR).
2022-07-27 Chinese
关于2021年限制性股票定向回购股份方案的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement from Jiangsu Deyuan Pharmaceutical Co., Ltd. regarding the repurchase and cancellation of restricted shares under the 2021 restricted stock incentive plan. It details the board and supervisory committee meetings approving the repurchase, the number of shares repurchased, the repurchase price, and the impact on share capital and equity structure. The document is a formal announcement of a share repurchase related to an equity incentive plan, including specifics about the shares and the rationale behind the repurchase. It is not a full financial report, earnings release, or management discussion, but rather a specific update on a capital action involving share repurchase and cancellation. Therefore, the appropriate classification is "Transaction in Own Shares (POS)" which covers company buybacks or sales of its own shares.
2022-07-27 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.